Pfizer cut to A+ by Fitch Ratings on debt repayment; Alexion wins FDA nod on new use for Soliris;

@FiercePharma: While the EU takes more time to weigh its Cephalon deal, Teva agrees to buy out Japanese JV partner for $150M. Story | Follow @FiercePharma

> Pfizer had its credit ratings cut by Fitch Ratings to A+ for failing to pay off more debt since its 2009 buyout of Wyeth. Report

> Alexion Pharmaceuticals won FDA approval for broader use of its Soliris drug, to treat a rare disorder, atypical hemolytic uremic syndrome. Report

> Dr. Reddy's Laboratories has called off its proposed deal to buy a portfolio of prescription drugs sold in Russia and the surrounding region from JB Chemicals & Pharmaceuticals. Report

> Orchid Pharmaceuticals said a fire at its facility in Chennai, India, struck a research lab and as such won't affect manufacturing operations. Report

> Japan's Asahi Kasei Pharma won regulatory approval to market a subcutaneous form of Teribone, an osteoporosis treatment in its home market. Report

> Chugai Pharmaceuticals, which has the rights to market Roche's Avastin in Japan, won a new indication for the drug in inoperable or recurrent breast cancer. Report

> Alkermes got an analyst upgrade in the wake of its acquisition of Elan's drug technologies unit. Report

> Sweden's Medivir tapped Maris Hartmanis as its new president and CEO; Hartmanis most recently CEO of the specialty pharma BioPhausia. Report

> Astellas Pharma and Optimer Pharmaceuticals said European regulators gave an initial nod to its Dificlir drug designed to treat C. difficile infection. Release

Biotech News

 @FierceBiotech: PacBio wants to offer sequencing machine users new cloud computing capabilities. Company is working with Cycle Computing. Story | Follow @FierceBiotech

 @RyanMFierce: Cancer drug shortages keep keep getting worse, bad trend for developers and patients. Report | Follow @RyanMFierce

 @MaureenFierce: Reading: Downsizing trend leaves pharma without the kinds of employees it needs. Story via @Pharmalot | Follow @MaureenFierce

> Elevation Pharma nabs $17M, recruits two key players. Report

> Report: FDA readies release of long-awaited rules on biosimilars. Item

> Roche R&D chief Garaud affirms $10B peak potential for HDL drug. Report

> Bayer's blockbuster Alpharadin may roil fast-changing prostate cancer field. News

Medical Device News

 @FierceMedDev: Neat! Diagnostic Development Unit Is A Star Trek-Style Sick Bay Bed via PSFK. Report | Follow @FierceMedDev

> Delcath taps Miao as CFO. Story

> Occlutech CEO scores win against St Jude-AGA Medical. Item

> Mela receives approvable letter for cancer device. Report

> Bausch + Lomb makes exec moves. News

> PENTAX launches first HD video bronchoscope. Story

Biotech IT News

> NextDocs expands to West Coast. Report

> PacBio reaches for cloud tech amid biz slump. Report

> Brain Resource scores $10M, opens SF office. News

> NIH backs tech linking trial data, patient records. Story

> Computational analysis points to potential HIV targets. Article

And Finally... A district judge tossed a lawsuit against Eli Lilly, in which a convicted murderer blamed the crime on Prozac. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.